On Target Laboratories has closed its series B round at $44m after an $11.1m extension featuring Helsinn, following an initial tranche led by Johnson & Johnson in September.

Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring an exit for Stanford University.

Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring exits for Alphabet, Novartis, Celgene and Taiho.

The cancer treatment startup, a spinoff of fusion energy system developer TAE Technologies, has publicly launched with an Artis-led series A round.

The capital will help push development of the Cornell University spinout's copolymer-based materials for nanofabrication.

Hanwang Technology is among the participants in a $15.8m round for the genetic testing services provider, which has now raised $23m in total.

The healthcare innovation services provider has joined forces with Tikehau Capital for a fund called TKS1 that has reached its first close.